Objective: Ranibizumab safety is well established for treatment of neovascular age-related macular degeneration (nAMD), but less is known about the risk of systemic serious adverse events (SAEs), specifically among patients with heightened baseline risk due to age (≥85 years). This analysis examines whether patients ≥85 years of age versus those <85 years experience an increased risk of key systemic SAEs during intravitreal ranibizumab treatment for nAMD.
Design: Retrospective, pooled analysis of safety data from 5 phase III/IIIb multicenter randomized clinical trials in patients with nAMD: ANCHOR, MARINA, PIER, SAILOR, and HARBOR.
Participants: Patients with nAMD receiving ranibizumab (n = 4347) or control (sham/verteporfin photodynamic therapy, n = 441) treatment included in the safety-evaluable set of the 5 trials.
Methods: The incidence of nonocular SAEs was analyzed stratified by age (<85 years [n = 3795] vs ≥85 years [n = 993]), treatment (control, ranibizumab 0.3 mg, ranibizumab 0.5 mg, ranibizumab 2.0 mg), and injection frequency (monthly, as needed [PRN]).
Main outcome measures: Incidence of key systemic SAEs, defined as total nonocular SAEs, deaths, cardiovascular events, cerebrovascular (CBV) events, and Antiplatelet Trialists' Collaboration events.
Results: The MARINA and ANCHOR trials had greater rates of key SAEs for patients ≥85 years versus those <85 years. Ranibizumab exposure did not increase the risk of most SAEs in elderly patients; for CBV events and death, the effect of ranibizumab versus control treatment for age ≥85 years was not interpretable due to small number of events (CBV: n = 2, 2, 5 for control, ranibizumab 0.3 mg, and ranibizumab 0.5 mg, respectively; death: n = 2, 4, 5, respectively). Across all 5 trials, an increased risk was found for age ≥85 years versus <85 years for the marketed dose of ranibizumab 0.5 mg. In the HARBOR trial, increased rates of key SAEs (excluding total nonocular SAEs) for age ≥85 years versus <85 years were observed with monthly dosing but not with PRN dosing; event rates were similar for 2.0 mg versus 0.5 mg.
Conclusions: Consistent with general trends, the risk of key systemic SAEs was associated with age ≥85 years versus <85 years, but not with ranibizumab drug exposure. The difference between monthly versus PRN was inconclusive. There was no evidence of a dose effect. Interpretation of this retrospective analysis is limited because it was not prospectively powered for statistically definitive conclusions.
Copyright © 2018 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Systemic Safety in Ranibizumab-Treated Patients With Neovascular Age-Related Macular Degeneration: A Patient-Level Pooled AnalysisMA Zarbin et al. Ophthalmol Retina 2 (11), 1087-1096. PMID 31047547.The rates of cardiovascular and cerebrovascular events were low in these patients with nAMD and not clinically meaningfully different for patients treated with ranibizuma …
Incidence of Retinal Pigment Epithelial Tears After Intravitreal Ranibizumab Injection for Neovascular Age-Related Macular DegenerationET Cunningham Jr et al. Ophthalmology 118 (12), 2447-52. PMID 21872935. - Clinical TrialAs studied in these trials, no statistically significant differences in the incidence of RPE tears within a 2-year treatment period were observed in patients who received …
Twelve-month Efficacy and Safety of 0.5 Mg or 2.0 Mg Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular DegenerationBG Busbee et al. Ophthalmology 120 (5), 1046-56. PMID 23352196. - Clinical TrialAt month 12, the ranibizumab 2.0 mg monthly group did not meet the prespecified superiority comparison and the ranibizumab 0.5 mg and 2.0 mg PRN groups did not meet the p …
Ranibizumab: Phase III Clinical Trial ResultsPJ Rosenfeld et al. Ophthalmol Clin North Am 19 (3), 361-72. PMID 16935211. - ReviewRanibizumab therapy is the first treatment for neovascular AMD to improve vision for most patients. The benefits apply to all angiographic subtypes of neovascular AMD and …
Ranibizumab: A Review of Its Use in the Treatment of Neovascular Age-Related Macular DegenerationJE Frampton. Drugs Aging 30 (5), 331-58. PMID 23539234. - ReviewRanibizumab (Lucentis(®)), an inhibitor of all vascular endothelial growth factor (VEGF) A isoforms, is approved for the intravitreal treatment of neovascular age-related …